Clinical Efficacy of Polycaprolactone β-Calcium Triphosphate Composite for Osteoconduction in Rabbit Bone Defect Model

Polymers

Huang-Chien Liang¹  Chia-Chun Wu²  Chiu-Ming Chen²  Shen-Mao Chen²  Shiou-Fu Lin³ 

[1] Department of Materials Engineering, Ming Chi University of Technology, New Taipei City 24301, Taiwan;Department of Orthopaedics, Tri-Service General Hospital, National Defense Medical Center, Taipei City 11490, Taiwan;Department of Pathology, Shuang-Ho Hospital, Taipei Medical University, Taipei City 23561, Taiwan;

关键词: β-tricalcium phosphate;    biocomposites;    osteoconduction;    polycaprolactone;   

DOI  :  10.3390/polym13152552

来源: DOAJ

【 摘 要 】

The combination of β-tricalcium phosphate (β-TCP) with polycaprolactone (PCL) has been considered a promising strategy for designing scaffolds for bone grafting. This study incorporated PCL with commercially available β-TCP (Osteocera^TM) to fabricate an injectable bone substitute and evaluate the effect of PCL on compressive strength and setting time of the hydraulic cement. The mechanical testing was compliant with the ASTM D695 and ASTM C191-13 standards. Results showed that PCL-TCP composite presented a well-defined architecture with uniform pore distribution and a significant increase in compressive strength compared with β-TCP alone. Eighteen rabbits, each with two surgically created bone defects, were treated using the PCL-TCP composites. The composite materials were resorbed and replaced by newly formed bone tissue. Both PCL-TCP and β-TCP demonstrated equivalent clinical effects on osteoconduction property in terms of the percentage of newly formed bone area measured by histomorphometric analysis. PCL-TCP was proven to be as effective as the commercially available β-TCP scaffold (Osteocera^TM).

【 授权许可】

Unknown